» Articles » PMID: 38822113

Structural, Dynamic Behaviour, In-vitro and Computational Investigations of Schiff's Bases of 1,3-diphenyl Urea Derivatives Against SARS-CoV-2 Spike Protein

Overview
Journal Sci Rep
Specialty Science
Date 2024 May 31
PMID 38822113
Authors
Affiliations
Soon will be listed here.
Abstract

The COVID-19 has had a significant influence on people's lives across the world. The viral genome has undergone numerous unanticipated changes that have given rise to new varieties, raising alarm on a global scale. Bioactive phytochemicals derived from nature and synthetic sources possess lot of potential as pathogenic virus inhibitors. The goal of the recent study is to report new inhibitors of Schiff bases of 1,3-dipheny urea derivatives against SARS COV-2 spike protein through in-vitro and in-silico approach. Total 14 compounds were evaluated, surprisingly, all the compounds showed strong inhibition with inhibitory values between 79.60% and 96.00% inhibition. Here, compounds 3a (96.00%), 3d (89.60%), 3e (84.30%), 3f (86.20%), 3g (88.30%), 3h (86.80%), 3k (82.10%), 3l (90.10%), 3m (93.49%), 3n (85.64%), and 3o (81.79%) exhibited high inhibitory potential against SARS COV-2 spike protein. While 3c also showed significant inhibitory potential with 79.60% inhibition. The molecular docking of these compounds revealed excellent fitting of molecules in the spike protein receptor binding domain (RBD) with good interactions with the key residues of RBD and docking scores ranging from - 4.73 to - 5.60 kcal/mol. Furthermore, molecular dynamics simulation for 150 ns indicated a strong stability of a complex 3a:6MOJ. These findings obtained from the in-vitro and in-silico study reflect higher potency of the Schiff bases of 1,3-diphenyl urea derivatives. Furthermore, also highlight their medicinal importance for the treatment of SARS COV-2 infection. Therefore, these small molecules could be a possible drug candidate.

Citing Articles

Synthesis, and study of novel 1,3-diphenylurea derived Schiff bases as competitive α-glucosidase inhibitors.

Pasha A, Ullah S, Khan A, Ahsan Halim S, Hussain J, Rehman T RSC Adv. 2024; 14(40):29288-29300.

PMID: 39285881 PMC: 11403393. DOI: 10.1039/d4ra05767h.


Schiff Bases Derived from Pyridoxal 5'-Phosphate and 2-X-Phenylamine (X = H, OH, SH): Substituent Effects on UV-Vis Spectra and Hydrolysis Kinetics.

Zavalishin M, Kiselev A, Gamov G Molecules. 2024; 29(15).

PMID: 39124909 PMC: 11314395. DOI: 10.3390/molecules29153504.

References
1.
Khalil R, Usmani S, Nur-E-Alam M, Ahmed S, Ul-Haq Z . Site-directed Fragnomics and MD Simulations Approaches to Identify Interleukin-2 Inhibitors. Med Chem. 2020; 17(4):407-417. DOI: 10.2174/1573406416999201113104501. View

2.
Morfin F, Thouvenot D . Herpes simplex virus resistance to antiviral drugs. J Clin Virol. 2003; 26(1):29-37. DOI: 10.1016/s1386-6532(02)00263-9. View

3.
Alwafi H, Naser A, Aldhahir A, Alhazmi A, Naif Alosaimi A, Abdulaziz Mandili R . COVID-19 vaccination side effects among the child age group: a large cross-sectional online based survey in Saudi Arabia. BMC Infect Dis. 2022; 22(1):911. PMC: 9724422. DOI: 10.1186/s12879-022-07905-2. View

4.
Muller W, Neufurth M, Schepler H, Wang S, Tolba E, Schroder H . The biomaterial polyphosphate blocks stoichiometric binding of the SARS-CoV-2 S-protein to the cellular ACE2 receptor. Biomater Sci. 2020; 8(23):6603-6610. DOI: 10.1039/d0bm01244k. View

5.
Ahsan Halim S, Waqas M, Khan A, Al-Harrasi A . In Silico Prediction of Novel Inhibitors of SARS-CoV-2 Main Protease through Structure-Based Virtual Screening and Molecular Dynamic Simulation. Pharmaceuticals (Basel). 2021; 14(9). PMC: 8471057. DOI: 10.3390/ph14090896. View